» Articles » PMID: 6220008

Human Plasma Lipoprotein [a]. Structural Properties

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1983 Apr 10
PMID 6220008
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

When lipoprotein [a] was isolated in the presence of the proteolytic inhibitor Trasylol, its apoprotein exhibited one dominant band corresponding to a molecular weight of about 1.2 million when analyzed by electrophoresis on 3.25% sodium dodecyl sulfate-polyacrylamide gels. After chemical reduction, this band was missing but was replaced by two bands, one corresponding to a molecular weight of about 490,000 and the other to a molecular weight of about 645,000. Before treatment with reducing agents, the apolipoprotein [a] and apolipoprotein B immunoreactivities were detectable in the same electrophoretic band, but after reduction the apolipoprotein [a] was demonstrated to be separate from the apolipoprotein B. These results suggest that the apoprotein of lipoprotein [a] is composed of two subunits which are similar in molecular weight and are held together by one or more disulfide bonds. One subunit possesses apolipoprotein [a] and the other apolipoprotein B immunoreactivity. The secondary structure of the apoprotein components within lipoprotein [a] has been studied by circular dichroism and found to differ significantly from the secondary structure of the apoproteins in low density lipoproteins and high density lipoproteins. About 30% alpha-helical structure was measured in lipoprotein [a] compared to 48% in low density lipoproteins and 70% in high density lipoproteins. Lipoprotein [a] exhibited a much higher percentage of disordered structure than either of the other two lipoproteins.

Citing Articles

Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease risk.

Behera S, Belyeu J, Chen X, Paulin L, Nguyen N, Newman E BMC Med Genomics. 2024; 17(1):255.

PMID: 39449055 PMC: 11515395. DOI: 10.1186/s12920-024-02024-0.


Frequency of lipoprotein(a) testing and its levels in Pakistani population.

Batool H, Khan M, Ain Q, Chughtai O, Khan M, Khan M Glob Cardiol Sci Pract. 2024; 2024(4):e202437.

PMID: 39351483 PMC: 11439424. DOI: 10.21542/gcsp.2024.37.


Recent progress in gene therapy for familial hypercholesterolemia treatment.

Luo Y, Hou Y, Zhao W, Yang B iScience. 2024; 27(9):110641.

PMID: 39262805 PMC: 11387600. DOI: 10.1016/j.isci.2024.110641.


Impact of Social Determinants of Health and Lifestyle on Association Between Lipoprotein(a) and Cardiovascular Events.

Brandt E, Kirch M, Patel N, Chennareddy C, Murthy V, Goonewardena S JACC Adv. 2024; 3(7):101016.

PMID: 39129977 PMC: 11313040. DOI: 10.1016/j.jacadv.2024.101016.


Lipoprotein(a) and Lung Function Are Associated in Older Adults: Longitudinal and Cross-Sectional Analyses.

Song C, Ohlei O, Keller T, Regitz-Zagrosek V, Toepfer S, Steinhagen-Thiessen E Biomedicines. 2024; 12(7).

PMID: 39062075 PMC: 11274407. DOI: 10.3390/biomedicines12071502.